Colorectal cancer
Clinical research in metastatic colorectal cancer, locally advanced rectal cancer, and resected colon cancer focuses on treatment selection across first-line, post-operative, and later-line settings. The portfolio also includes RAS and BRAF-defined disease, HER2-positive tumours, and biomarker-selected populations.
- Metastatic colorectal cancer
- ctDNA-guided treatment
- Anti-EGFR therapy
- Adjuvant treatment
Research interest extends to immunotherapy, targeted therapy, and treatment sequencing in patients with recurrent or unresectable disease.
Gastric and gastroesophageal cancer
Trials address gastric cancer and gastroesophageal junction cancer in resectable and locally advanced settings, with attention to microsatellite instability and post-surgical residual disease. The research landscape includes perioperative and definitive approaches for tumours with distinct molecular features.
- Resectable gastric cancer
- Microsatellite instability-high disease
- Minimal residual disease
- Perioperative therapy
These studies reflect interest in integrating immunotherapy and antibody-drug conjugates within surgical cancer care.
Hepatobiliary and pancreatic malignancies
Research activity includes advanced pancreatic cancer, liver-limited unresectable colorectal cancer, and resectable biliary tract cancers. The sponsor’s portfolio examines both systemic treatment strategies and liver-directed approaches in patients with limited metastatic spread or high recurrence risk.
- Advanced pancreatic cancer
- Biliary tract cancer
- Liver-directed therapy
- Maintenance treatment
There is also interest in combining chemotherapy with targeted agents in settings where surgery remains part of the treatment pathway.
Rare solid tumours and hereditary skin cancer syndromes
The trial portfolio extends beyond gastrointestinal oncology to Merkel cell carcinoma and Nevoid Basal Cell Carcinoma Syndrome, including sporadic and syndrome-associated basal cell carcinoma. These studies focus on operable disease and treatment approaches for uncommon tumours with specific molecular or inherited backgrounds.
- Merkel cell carcinoma
- Basal cell carcinoma
- Gorlin syndrome
- Operable rare cancers
Interest in this area includes immune-based treatment and hedgehog pathway inhibition.
Molecularly guided oncology
Several studies are centered on ctDNA, molecular selection, and tumour-specific biomarkers to refine treatment choice in colorectal cancer and HER2-positive disease. This includes research in patients with BRAF V600E mutation, RAS/BRAF wild-type tumours, and biomarker-defined resectable cancers.
- Circulating tumour DNA
- HER2-positive disease
- BRAF V600E mutation
- Biomarker-selected therapy
The research emphasis includes precision oncology in both metastatic and post-operative settings.
